# Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma

> **NCT02645864** · PHASE1 · COMPLETED · sponsor: **Peking University** · enrollment: 12 (actual)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Apatinib
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT02645864
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2018-12
- **Final completion:** 2018-12
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2021-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02645864

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02645864, "Apatinib and Irinotecan Combination Treatment in Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT02645864. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*